"We perform gene editing in primary human immune cells for basic research, drug discovery, and to develop new cell therapies. Cergentis has helped us characterize the on- and off-target integrations when non-virally targeting new genetic material into human T cells with CRISPR, aiding our push towards clinical translation."

University of California, San Francisco
Alexander Marson, MD, PhD - Director of the Gladstone-UCSF Institute of Genomic Immunology

"TLA outperforms traditional methods used in CHO cell line characterisation and provides higher resolution and sensitivity.”

Dr. Stefanie Bartels - Project Leader Cell Line Development
  • Latest news

  • Empowering advanced genetic engineering
    precision medicine

  • Upcoming events

    28 | 10 | 2021 / 29 | 10 | 2021 - Conferences
    Read more

    Read more
  • TLA technology

    Read more
  • Publications

    Read more
© 2012-2021 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.